Claims:

1. An anti-CSF-1R antibody comprising: a heavy chain, wherein the heavy chain comprises the sequence given in SEQ ID NO:23; and a light chain, wherein the light chain comprises the sequence given in SEQ ID NO:15.

2. The anti-CSF-1R antibody according to claim 1, wherein the antibody molecule is selected from the group consisting of: a complete antibody molecule having full length heavy and light chains or a fragment thereof, for example selected from the group comprising a Fab, modified Fab', Fab', $F(ab')_2$, Fv, VH, VL and scFv fragment.

3. The anti-CSF-1R antibody according to claims 1 or 2 having a heavy chain comprising the sequence given in SEQ ID NO:27 and a light chain comprising the sequence given in SEQ ID NO:19.

4. The anti-CSF-1R antibody according to any one of claims 1 to 3, having an effector or a reporter molecule attached to it.

5. The anti-CSF-1R antibody according to any one of claims 1 to 4, having a binding affinity for human CSF-1R of 10pM or less than 10pM.

6. An anti-CSF-1R antibody which cross-blocks the binding of an antibody comprising the 6 CDRs given in sequence SEQ ID NO:1 for CDR-L1, SEQ ID NO:2 for CDR-L2, SEQ ID NO:3 for CDR-L3, SEQ ID NO:4 for CDR-H1, SEQ ID NO:5 for CDR-H2 and SEQ ID NO:6 for CDR-H3, for example with affinity of 100pM or less; wherein optionally the antibody cross-blocks the binding by binding the same epitope as the antibody which it blocks.

7. An isolated DNA sequence encoding the heavy and/or light chain(s) of an antibody according to any one of claims 1 to 5.

8. A cloning or expression vector comprising one or more DNA sequences according to claim 7.

9. A vector according to claim 8, wherein the vector comprises the sequences given in SEQ ID NO:28 and/or SEQ ID NO:20.

10. A host cell comprising one or more cloning or expression vectors according to claim 9.

11. A process for the production of the antibody of any one of claims 1 to 5, comprising culturing the host cell of claim 10 and isolating the antibody.

12. A pharmaceutical composition comprising an antibody according to any one of claims 1 to 5, in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.

13. A pharmaceutical composition according to claim 12, additionally comprising other active ingredients.

14. An antibody according to any one of claims 1 to 5 or a composition according to claim 12 for use as a medicament.

15. An antibody according to any one of claims 1 to 5 or a composition according to claim 12 for use in the treatment of cancer or a fibrotic disease.

16. The antibody or the composition for use according to claim 15, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, bone cancer, colorectal cancer, leukaemia, lymphoma, skin cancer, esophageal cancer, gastric cancer, astrocytic cancer, endometrial cancer, cervical cancer, bladder cancer, renal cancer, lung cancer, liver cancer, thyroid cancer, head and neck cancer, pancreatic cancer and ovarian cancer.

17. The antibody or the composition for use according to claim 15, wherein the fibrotic disease is selected from the group consisting of pulmonary fibrosis such as idiopathic pulmonary fibrosis and cystic fibrosis, renal fibrosis, liver cirrhosis, endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, Crohn's disease, keloid, myocardial infarction, scleroderma and arthrofibrosis.

18. Use of the antibody according to any one of claims 1 to 5 or the composition according to claim 12 in the manufacture of a medicament for the treatment of cancer or a fibrotic disease.

19. The use according to claim 18, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, bone cancer, colorectal cancer, leukaemia, lymphoma, skin cancer, esophageal cancer,

gastric cancer, astrocytic cancer, endometrial cancer, cervical cancer, bladder cancer, renal cancer, lung cancer, liver cancer, thyroid cancer, head and neck cancer, pancreatic cancer and ovarian cancer.

20. The use according to claim 18, wherein the fibrotic disease is selected from the group consisting of pulmonary fibrosis such as idiopathic pulmonary fibrosis and cystic fibrosis, renal fibrosis, liver cirrhosis, endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, Crohn's disease, keloid, myocardial infarction, scleroderma and arthrofibrosis.